In colorectal cancer, Luxembourg has one of the lowest rates of emergency diagnosis among screening-age patients. Photo: Shutterstock

In colorectal cancer, Luxembourg has one of the lowest rates of emergency diagnosis among screening-age patients. Photo: Shutterstock

An OECD report, ‘Delivering High Value Cancer Care’, highlights Luxembourg as a high-spending, high-capacity system increasingly exposed to the risks of overdiagnosis, overtreatment and rising long-term costs. The findings suggest that the country’s next cancer policy challenge lies less in access to care than in managing value.

Luxembourg’s cancer system combines broad access with some of the highest per-capita spending in the European Union. According to a new OECD and European Commission analysis, those strengths also place high-income systems such as Luxembourg among those most exposed to a growing policy risk: ensuring that intensive screening and treatment deliver proportional gains in outcomes and quality of life.

The findings are set out in Delivering High Value Cancer Care: European Cancer Inequalities Registry Analytical Report, published in 2026 with the support of the European Commission, which examines how cancer systems across the EU are coping with rising incidence, longer survival and mounting cost pressures.

From access to value

Cancer diagnoses across the European Union have risen sharply over the past two decades, while spending on cancer care continues to climb. The report’s central argument is that as access improves and survival increases, policy attention must shift towards variation in clinical practice and the growing share of care that delivers limited additional benefit.

Luxembourg features in the report as a high-spending case, alongside countries such as Germany. That investment has supported wide access to diagnostics and treatment and contributed to improved survival. But the OECD warns that intensive screening and low treatment thresholds can also increase the risk of overdiagnosis and overtreatment, particularly in cancers where survival gains are marginal for older patients.

A clear illustration

Prostate cancer is cited as a clear illustration. Among men aged 75 and over, Luxembourg records one of the highest shares of early-stage prostate cancer diagnoses in Europe. The report does not assess national policy choices, but situates this pattern within a broader concern about aggressive intervention with limited impact on survival and significant consequences for quality of life.

The contrast with countries such as the Netherlands, where a smaller share of older men are diagnosed at an early stage, underlines the report’s broader point: large variations in clinical practice that cannot be fully explained by patient needs or preferences.

The analysis also identifies areas of relative strength. In colorectal cancer, Luxembourg has one of the lowest rates of emergency diagnosis among screening-age patients, pointing to effective population screening and timely access to care. However, outside those age groups, late diagnosis remains common across Europe, reflecting gaps in diagnostic pathways for younger patients as early-onset cancers rise.

Neighbours as reference points

International comparisons are used as policy reference points rather than rankings. Belgium is cited for its emphasis on hospital-level quality monitoring, while France is highlighted for efforts to redesign care pathways and shift treatment out of hospitals. Germany, which combines high spending with broad access and treats many Luxembourg patients under cross-border insurance arrangements, is presented more cautiously, with persistent variation in outcomes despite scale and investment.

The report stops short of calling for reduced spending or restricted access. Instead, it argues that high-income systems now face a different challenge: deciding where intervention adds value, and where restraint may better serve patients, quality of life and long-term sustainability.